Limited data are available on the risk of pancreatic adverse events among people with obesity or type 2 diabetes mellitus (T2DM) initiating glucagon-like peptide-1 receptor agonist (GLP-1 RA). Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.